Supplementary Table 2. Baseline characteristics of the study population; subgroups are defined by the treatment status at end of follow-up.

	Treatment subgroups at end of follow-up										
	α-blocker median (P_{25}–P_{75})		5-α-reductase median (P_{25}–P_{75})		Surgery inhibitors median (P_{25}–P_{75})		Watchful waiting median (P_{25}–P_{75})		Not according to protocol (P_{25}–P_{75})		Watchful waiting (i)[a] median (P_{25}–P_{75})
	intervention (*n* = 25)	control (*n* = 6)	intervention (*n* = 1)	control (*n* = 0)	intervention (*n* = 2)	control (*n* = 4)	intervention (*n* = 39)	control (*n* = 86)	intervention (*n* = 31)	control (*n* = 0)	intervention (*n* = 69)
Age in years	63 (60–68)	69 (63–73)	68 -	- -	76	70 (60–74)	64 (61–71)	64 (60–70)	66 (60–71)	- -	64 (60–71)
IPSS	13 (11–18)	14 (11–21)	32 -	- -	14 (13–15)	12 (9–20)	11 (9–14)	13 (10–17)	15 (11–19)	- -	12 (10–16)
Q_{max}	9.2 (7.0–16.2)	14.1 (8.9–23.8)	8.1 -	- -	4.3 (4.3–4.3)	10.9 (3.9–16.1)	11.6 (7.6–15)	12.8 (8.2–16.6)	12.0 (7.6–18.1)	- -	11.6 (8.0–17.5)
Dan-PSS	8 (4–15)	19 (11–24)	71 -	- -	27 (22–32)	9 (3–23)	8 (2–12)	8 (5–18)	12 (5–20)	- -	9 (4–17)
Prostate size, ml	25 (18–32)	25 (21–36)	87 -	- -	27	31 (23–69)	23 (17–29)	24 (20–31)	26 (19–32)	- -	24 (18–32)
Post-void residual Volume (ml)	51 (34–82)	33 (17–97)	308 -	- -	21 -	42 (40–55)	23 (12–58)	39 (19–72)	31 (20–52)	- -	28 (13–56)
PSA, ng/ml	1.0 (0.7–1.7)	1.5 (0.8–3.7)	3.4 -	- -	2.2 -	3.0 (1.9–5.8)	1.0 (0.6–1.7)	1.2 (0.7–1.8)	1.3 (0.7–2.3)	- -	1.1 (0.7–2.0)

[a]*Watchful waiting (i) = pooled data from all who were on watchful waiting at end of follow-up, that is, 39 subjects from the watchful waiting subgroup according to the treatment protocol, and 30 (of 31) subjects from the not-according-to-protocol subgroup. IPSS = International Prostate Symptom Score; Q_{max} = maximum urinary flow rate; Dan-PSS = Danish Prostate Symptom Score; PSA = prostate specific antigen. All significance values of the differences between intervention and control group within a treatment subgroup were P ≥0.05.*